Data / Form D filings / Nuclein, LLC
Nuclein, LLC: Form D filings
Nuclein, LLC, a biotechnology company in Austin, TX, filed 16 Form D notices with the SEC between 2019 and 2026. The latest, on October 27, 2026, reports $15.7 million sold of a $26.1 million offering to 25 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 8305 CROSS PARK DR, Austin, TX, 78754
- Phone
- (512) 879-3301
- Industry
- Biotechnology
- Entity type
- Limited Liability Company
- Incorporated in
- Texas
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1787352
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | Amendment | $26,114,842 | $15,650,488 | $10,464,354 | 25 | Jun 4, 2026 | sec.gov |
| Aug 14, 2026 | Amendment | $16,114,842 | $9,253,488 | $6,861,354 | 15 | Jun 4, 2026 | sec.gov |
| Jun 22, 2026 | New notice | $11,114,842 | $1,295,000 | $9,819,842 | 2 | Jun 4, 2026 | sec.gov |
| Apr 27, 2026 | Amendment | $25,000,000 | $19,065,157 | $5,934,843 | 49 | Jul 1, 2025 | sec.gov |
| Feb 5, 2026 | Amendment | $15,000,000 | $9,392,180 | $5,607,820 | 34 | Jan 23, 2025 | sec.gov |
| Dec 17, 2025 | Amendment | $20,000,000 | $14,904,000 | $5,096,000 | 42 | Jul 1, 2025 | sec.gov |
| Oct 14, 2025 | Amendment | $15,000,000 | $9,779,000 | $5,221,000 | 37 | Jul 1, 2025 | sec.gov |
| Jun 30, 2025 | New notice | $10,000,000 | $0 | $10,000,000 | 0 | Yet to occur | sec.gov |
| Feb 3, 2025 | New notice | $15,000,000 | $750,000 | $14,250,000 | 3 | Jan 23, 2025 | sec.gov |
| Aug 5, 2024 | Amendment | $15,000,000 | $8,788,151 | $6,211,849 | 18 | Dec 15, 2023 | sec.gov |
| Nov 17, 2023 | New notice | $10,000,000 | $0 | $10,000,000 | 0 | Yet to occur | sec.gov |
| Mar 23, 2023 | New notice | Indefinite | $0 | 0 | Yet to occur | sec.gov | |
| Jul 12, 2022 | New notice | Indefinite | $0 | 0 | Yet to occur | sec.gov | |
| Jan 19, 2021 | New notice | Indefinite | $0 | 0 | Yet to occur | sec.gov | |
| Feb 18, 2020 | New notice | $1,000,000 | $0 | $1,000,000 | 0 | Yet to occur | sec.gov |
| Sep 10, 2019 | New notice | Indefinite | $420,012 | 10 | Aug 26, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Alan Blake | Executive Officer, Director | |
| Richard Crockett | Director | |
| William Cunningham | Director | |
| Douglas Bryant | Director | |
| Sanjay Chandra | Director | |
| H. David Shockley | Director | |
| Walter Narajowski | Director | |
| Jeffrey Stukuls | Executive Officer |
Other biotechnology companies in Texas that filed recently
- OncoNano Medicine, Inc. $10.1 million · Oct 8, 2026
- Solaris Endovascular Inc. $5 million · Oct 1, 2026
- Hera Biotech, Inc. $1.7 million · Sep 23, 2026
- Kayak Therapeutics, Inc. $25 million · Aug 21, 2026
- InnovoTEX Inc. $2.7 million · Aug 18, 2026
- BioGene Therapeutics Inc. $3 million · Aug 7, 2026
Every Form D from the week of Oct 26, 2026 · All recent filings in Texas · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Nuclein, LLC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.